AZD2171: a highly potent, orally bioavailable, vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor for the treatment of cancer.

By S. Wedge, J. Kendrew, L. Hennequin, P. J. Valentine, S. Barry, S. Brave, Neil R. Smith, N. James, M. Dukes, J. Curwen and 14 more. Cancer Research, 2005

715 citations recorded by the source corpus.

Subfields: Molecular Biology, Oncology

View Paper: https://www.semanticscholar.org/paper/2d8c15838f8013407a0750b7e3287adac142f9d3

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Molecular Biology

1. Rakesh K. Jain
2. D. Duda
3. Jay S. Loeffler
4. E. di Tomaso
5. P. Wen
6. D. Louis
7. D. Scadden
8. Dai Fukumura

In Oncology

1. Rakesh K. Jain
2. D. Duda
3. Jay S. Loeffler
4. E. di Tomaso
5. D. Louis
6. D. Scadden
7. Triantafyllos Stylianopoulos
8. Dai Fukumura

Citations in the corpus

• AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients. (2007, methodology): “To this end, we designed a National Cancer Institute-sponsored phase II clinical trial of AZD2171 (cediranib, AstraZeneca Pharmaceuticals, UK; Wedge et al., 2005)—a potent oral, pan-VEGF receptor tyrosine kinase inhibitor with activity against PDGF receptors and c-Kit —in glioblastoma patients who…”